Biogen

BIIB

Cambridge, United States· Est. 1978

biogen.com

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

BIIB · Stock Price

USD 190.68+72.29 (+61.06%)

Market Cap: $28.2B

Historical price data

Market Cap: $28.2BPipeline: 200 drugs (101 Phase 3)Patents: 20Founded: 1978Employees: Over 1,300 R&D professionals (global total not specified)HQ: Cambridge, United States

Sector Ranking#61 in Biologics / Biosimilars #3 in RNA Therapeutics (non-mRNA)

Overview

Founded in 1978, Biogen has established itself as a cornerstone of the biotechnology industry, renowned for pioneering multiple sclerosis treatments and launching the first approved therapy for Alzheimer's disease. The company's strategy is anchored in a focused R&D engine that reinvests approximately $2 billion annually into neurology, immunology, and rare disease pipelines, balancing bold scientific risk with disciplined capital allocation. Its mission is to translate cutting-edge science into transformative medicines, creating value for patients, shareholders, and communities.

NeurologyImmunologyRare Diseases

Technology Platform

A biology-first, multi-modality platform organized around 'Drug Hunters' for target identification and 'Drug Architects' for therapeutic design, with expertise in antisense oligonucleotides (ASOs), monoclonal antibodies, and small molecules.

Pipeline

200

200 drugs in pipeline101 in Phase 3

Drug	Indication	Stage
peginterferon beta-1a	Relapsing Multiple Sclerosis	Phase 3
Simvastatin	Relapsing Remitting Multiple Sclerosis	Phase 3
ALKS 8700 + Dimethyl Fumarate	Relapsing Remitting Multiple Sclerosis	Phase 3
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg C...	Postpartum Depression	Phase 3
Bardoxolone methyl	Pulmonary Hypertension	Phase 3

Funding History

Total raised:$750M

Debt$750MUndisclosedMay 15, 2020

IPOUndisclosedUndisclosedSep 15, 1991

FDA Approved Drugs

TOFIDENCEBLASep 29, 2023

ZURZUVAENDAAug 4, 2023

QALSODYNDAApr 25, 2023

Opportunities

Near-term growth is driven by the global launch of Leqembi in the vast Alzheimer's market and late-stage immunology assets from the HI-Bio acquisition.

Long-term opportunity lies in developing potentially curative MS therapies and expanding the immunology franchise into new autoimmune indications.

Risk Factors

Major risks include clinical/regulatory failure of key pipeline assets, slower-than-expected commercial adoption of Leqembi due to access and infrastructure hurdles, intense competition in core therapeutic areas, and revenue erosion from legacy MS patent expiries.

Competitive Landscape

Biogen faces intense competition from large pharma (Eli Lilly, Roche in Alzheimer's; Roche, Novartis in MS) and biotech innovators. Its strategy is to leverage deep neurology/immunology expertise and targeted acquisitions to compete in high-unmet-need niches rather than broad markets.